Bernstein raised the firm’s price target on Tandem Diabetes (TNDM) to $25 from $18 and keeps a Market Perform rating on the shares. After a low point in September 2025, U.S. healthcare stocks have begun to perform better over the past several months, the firm notes. As the market gets more clarity on many of the macro / policy uncertainties that weighed on healthcare stocks during the course of 2025, Bernstein anticipates better days ahead for healthcare stocks in 2026.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes price target raised to $25 from $16 at Goldman Sachs
- Tandem Diabetes Care Targets Longer-Wear Infusion Sets in New Home-Use Study
- Tandem Diabetes Care Updates Bylaws, Tightens Governance Rules
- Tandem Diabetes price target raised to $24 from $17 at Truist
- Tandem Diabetes price target raised to $30 from $25 at RBC Capital